Treatment of Short Stature with Aromatase Inhibitors: A Systematic Review and Meta-Analysis

Abstract

The objective of the study is to determine the risks and benefits of treating idiopathic short stature (ISS) with aromatase inhibitors (AIs). We comprehensively searched PubMed, Embase, and the China National Knowledge Infrastructure between establishment year and January 31, 2020. Mean difference (MD)/Standardized mean differences (SMD) with 95% confidence intervals (CI) of individual studies were pooled using fixed or random effects models. Subgroup and sensitivity analyses were also performed. Publication bias was estimated using funnel plots and Egger tests. Fourteen studies including 388 participants were included. The meta-analysis results showed that AIs significantly increased final height (MD=2.46, 95% CI: 0.8–4.12) and predicted adult height (MD=0.34, 95% CI: 0.11–0.57). Changes in bone age (MD=–0.1, 95% CI: –0.86–0.66) and bone mineral density (MD=–0.05, 95% CI: –0.19–0.1) were not different between intervention and control group. AI significantly increased testosterone level (SMD=2.01, 95% CI: 0.8–3.23) and reduced estradiol level (SMD=–1.13, 95% CI: –1.87 to –0.40); The intervention and control group had no significant differences in the levels of high-density lipoprotein-cholesterol (SMD=–0.31, 95%CI: –0.68–0.06) and IGF-1 (SMD=0.7, 95% CI: –0.66–2.06) levels. Adverse events were more frequent in the intervention group than in the control group (odds ratio=3.12, 95% CI: 1.44–6.73). In conclusion, both AI monotherapy and AI combination therapy can increase predicted adult height and testosterone levels.

Key words

aromatase inhibitors - short stature - final height - predicted adult height

^* Jing Liu and Shujuan Yin are joint first authors.

^# Hui Pan and Huijuan Ma contributed equally to this manuscript.

Publication History

Received: 02 August 2020

Accepted after revision: 14 April 2021

Article published online:
21 June 2021

• References

• 1 Barstow C, Rerucha C. Evaluation of Short and Tall Stature in Children. Am Fam Physician 2015; 92: 43-50
• 2 Hussein A, Farghaly H, Askar E. et al. Etiological factors of short stature in children and adolescents: experience at a tertiary care hospital in Egypt. Therap. Adv Endocrinol Metab 2017; 8: 75-80
• 3 Lashari SK, Korejo HB, Memon YM. To determine frequency of etiological factors in short statured patients presenting at an endocrine clinic of a tertiary care hospital. Pakistan J Med Sci 2014; 30: 858-861
• 4 Hero M, Maury S, Luotoniemi E. et al. Cognitive effects of aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol 2010; 163: 149-155
• 5 Benabbad I, Rosilio M, Tauber M. et al. Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature. Endocr Connect 2018; 7: 708-718
• 6 Colmenares A, González L, Gunczler P. et al. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?. J Pediatr Endocrinol Metab 2012; 25: 651-657
• 7 Inzaghi E, Reiter E, Cianfarani S. The Challenge of Defining and Investigating the Causes of Idiopathic Short Stature and Finding an Effective Therapy. Horm Res Paediatr 2019; 92: 71-83
• 8 Li P, Li Y, Yang CL. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: A meta-analysis. Medicine (Baltimore) 2014; 93: e260
• 9 Child CJ, Quigley CA, Cutler GB. et al. Height Gain and Safety Outcomes in Growth Hormone-Treated Children with Idiopathic Short Stature: Experience from a Prospective Observational Study. Horm Res Paediatr 2019; 91: 241-251
• 10 Mauras N, Gonzalez de Pijem L, Hsiang HY. et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab 2008; 93: 823-831
• 11 Wickman S, Sipila I, Ankarberg-Lindgren C. et al. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 2001; 357: 1743-1748
• 12 Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 6396
• 13 Merke DP, Keil MF, Jones JV. et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85: 1114-1120
• 14 Zhao X, Zhang Q. Clinical efficacy of letrozole in boys with idiopathic central precocious puberty Available at: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01117055/full
• 15 McGrath N, O’Grady MJ. Aromatase inhibitors for short stature in male children and adolescents. The Cochrane database of systematic reviews 2015; Cd010888 doi:
• 16 Rothenbuhler A, Linglart A, Bougneres P. A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature. Int J Pediatr Endocrinol 2015; 2015: 4
• 17 Hero M, Toiviainen-Salo S, Wickman S. et al. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty. J Bone Miner Res 2010; 25: 1536-1543
• 18 Varimo T, Toiviainen-Salo S, Raivio T. et al. Letrozole Monotherapy in Pre- and Early-Pubertal Boys Does Not Increase Adult Height. Front Endocrinol 2019; 10: 201
• 19 Ferris JA, Geffner ME. Are aromatase inhibitors in boys with predicted short stature and/or rapidly advancing bone age effective and safe?. J Pediatr Endocrinol Metab 2017; 30: 311-317
• 20 Hero M, Makitie O, Kroger H. et al. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm Res 2009; 71: 290-297
• 21 Mauras N, Ross JL, Gagliardi P. et al. Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature. J Clin Endocrinol Metab 2016; 101: 4984-4993
• 22 Hero M, Wickman S, Dunkel L. Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006; 64: 510-513
• 23 Rohani F, Asadi R, Mirboluk AA. et al. Letrozole Effect on Final Height of Patients with Constitutional Delay of Growth and Puberty. Med Arch 2019; 73: 307-310
• 24 Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab 2003; 88: 3785-3793
• 25 Salehpour S, Alipour P, Razzaghy-Azar M. et al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr 2010; 74: 428-435
• 26 Dunkel L, Wickman S. Novel treatment of short stature with aromatase inhibitors. J Steroid Biochem Mol Biol 2003; 86: 345-356
• 27 Santen RJ, Brodie H, Simpson ER. et al. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009; 30: 343-375
• 28 Geisler J, Haynes B, Anker G. et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002; 20: 751-757
• 29 Neely EK, Kumar RB, Payne SL. et al. Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. J Clin Endocrinol Metab 2014; 99: 4086-4093
• 30 Cui YP, Wang XL. Clinical effect of letrozole in treatment of idiopathic short stature in adolescent boys. Zhongguo Dang Dai Er Ke Za Zhi 2019; 21: 977-982
• 31 Varimo T, Huopio H, Kariola L. et al. Letrozole versus testosterone for promotion of endogenous puberty in boys with constitutional delay of growth and puberty: a randomised controlled phase 3 trial. Lancet Child Adolesc Health 2019; 3: 109-120
• 32 Hero M. Aromatase Inhibitors in the Treatment of Short Stature. Endocr Dev 2016; 30: 130-140
• 33 Shams K, Cameo T, Fennoy I. et al. Outcome analysis of aromatase inhibitor therapy to increase adult height in males with predicted short adult stature and/or rapid pubertal progress: a retrospective chart review. J Pediatr Endocrinol Metab 2014; 27: 725-730
• 34 Shim KS. Pubertal growth and epiphyseal fusion. Ann Pediatr Endocrinol Metab 2015; 20: 8-12
• 35 Borjesson AE, Windahl SH, Karimian E. et al. The role of estrogen receptor-alpha and its activation function-1 for growth plate closure in female mice. Am J Physiol Endocrinol Metab 2012; 302: E1381-E1389
• 36 Borjesson AE, Lagerquist MK, Windahl SH. et al. The role of estrogen receptor alpha in the regulation of bone and growth plate cartilage. Cell Mol Life Sci 2013; 70: 4023-4037
• 37 Mauras N, Bishop K, Merinbaum D. et al. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab 2009; 94: 2975-2978
• 38 de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol 2011; 9: 93
• 39 Li XF, Wang SJ, Jiang LS. et al. Gender- and region-specific variations of estrogen receptor alpha and beta expression in the growth plate of spine and limb during development and adulthood. Histochem Cell Biol 2012; 137: 79-95
• 40 Ramadorai U, Hire J, DeVine JG. et al. Incidental findings on magnetic resonance imaging of the spine in the asymptomatic pediatric population: a systematic review. Evidence-Based Spine-Care J 2014; 5: 95-100
• 41 Kil KE, Biegon A, Ding YS. et al. Synthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug. Nuclear. Med Biol 2009; 36: 215-223
• 42 Goudriaan AE, Lapauw B, Ruige J. et al. The influence of high-normal testosterone levels on risk-taking in healthy males in a 1-week letrozole administration study. Psychoneuroendocrinology 2010; 35: 1416-1421